Find this video on youtube

Source links:

What’s Next For COVID Vaccines With Tonix Pharmaceuticals’ Seth Lederman, M.D.

Tonix Pharmaceuticals’ CEO Reveals Next-Generation COVID Vaccine Technology chosen for key program

Tonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Tonix Pharmaceuticals pipeline

Project NextGen Enhancing Preparedness for Future COVID-19 Strains & Variants with Next Generation Medical Countermeasures

Project NextGen Selects Initial Vaccine Candidates and Awards Over $500 Million to Advance Development of Vaccines and Therapeutics

Project NextGen: Director Robert Johnson Introduction